# Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

> **NCT07674290** · PHASE4 · RECRUITING · sponsor: **Tom Hühne** · enrollment: 200 (estimated)

## Conditions studied

- Bardet Biedl Syndrome (BBS)
- Bardet Biedl Syndrome
- Bardet-Biedl Syndrome (BBS)
- Alstrom Syndrome

## Interventions

- **DRUG:** Setmelanotide

## Key facts

- **NCT ID:** NCT07674290
- **Lead sponsor:** Tom Hühne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674290, "Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*